Key points are not available for this paper at this time.
Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Toni K. Choueiri
Piotr Tomczak
Se Hoon Park
New England Journal of Medicine
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
University of Michigan
University College London
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Choueiri et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8901105ee2ba81dbefbb3 — DOI: https://doi.org/10.1056/nejmoa2106391